Study assessing real-world data relating to the efficacy of antiangiogenic drugs for the treatment of patients with Thymic carcinoma
Latest Information Update: 24 Jan 2023
At a glance
- Drugs Catequentinib (Primary) ; Rivoceranib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
Most Recent Events
- 24 Jan 2023 New trial record
- 05 Jan 2023 Results published in the BMC Cancer